AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06254924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QI App Users
Description: QI App users will be asked to complete a daily, 2-question mood and stress survey. They will be encouraged to use the QI App to practice mindfulness skills including meditation, drawing, coloring, breathing, and walking. They will be encouraged to use the QI App to help them participate in asynchronous group running activities.
Study NCT06254924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents/Guardians of QI App Users
Description: Parents/Guardians of QI App users will be informed that their child is using the QI App for a 6-week period.
Study NCT05158348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride
Description: Group A will receive post-operative nebulised dexametomidine and lidocaine.
Study NCT05158348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized lidocaine
Description: Group B will receive post-operative will receive nebulised lidocaine
Study NCT05158348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration of lidocaine
Description: group C will receive intra-operative local infiltration of lidocaine
Study NCT05430867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Oral Tablet
Description: Memantine 20mg once-daily
Study NCT05430867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV-971 capsule
Description: GV-971 450mg twice a day
Study NCT05954754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing Exercises
Description: Diaphragmatic breathing exercise training was given individually to each pregnant women in the experimental group by one of the trained researchers. Two weeks after the first application, the researcher made the pregnant woman repeat the application 2 days a week via video call. Thus, a total of five diaphragmatic breathing exercises were applied to pregnant women in the experimental group during two weeks. They continued to do breathing exercises for 20-30 minutes a day for ten minutes each day for two weeks as they could tolerate.
Study NCT04974307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrCam MyEye 2
Description: The OrCam MyEye 2 is a 22.5-g portable, eyeglass-mounted device that converts camera-captured inputs to auditory outputs. Its advertised functions include text reading, facial recognition, and product identification.
Study NCT06004661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAA617
Description: Administered intravenously once every cycles (1 cycle = 6 weeks)
Study NCT06004661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: Single intravenous dose of approximately 150 MBq
Study NCT05446298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC-392
Description: ONC-392 will be given by IV infusion, q3w.
Study NCT05446298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab in fixed dose of 200 mg will be given by IV infusion, q3w.
Study NCT06008704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Clinical assessment
Description: The clinical assessment consists on behavioural and motor evaluations to determine the characteristics of the population
Study NCT06008704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pain characteristics assessment
Description: The pain characteristics assessment will be made with a variety of scales and questionnaires which allow to identify the extent of central pain and functional impairment
Study NCT06008704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: The MRI examination allows anatomical imaging, diffusion imaging and functional imaging to measure specific markers
Study NCT06008704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Thermotest
Description: The thermotest is performed to assess the pain perception threshold
Study NCT06008704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: UPDRS-III Scale
Description: The UPDRS-III scale allows to asses motor functionality of PD patients
Study NCT06008704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: [18F]-MPPF PET scan
Description: The PET scan after injection of \[18F\]-MPPF at a dose of 200 Megabecquerel/kg +/-10% allows in vivo imaging of 5HT1A receptors
Study NCT06664502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYE201
Description: EYE201 solution for intravitreal administration
Study NCT05139524 — intervention group
Intervention type: OTHER
Intervention: Evidence of past or recent RVF exposure
Description: Detection of RVF exposure.
Study NCT06604026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD PosiFlush™ SafeScrub
Description: Clinicians will be advised to use BD PosiFlush™ SafeScrub as per the Instructions for Use for the treatment arm of the study.~An independent nurse observer will observe and document any adverse events (e.g.~local skin reaction, or irritation, or allergic response, up to and including symptoms of anaphylaxis), compliance with needleless access device scrubbing before flushing, device success rate (encapsulation and removal) as well as the time requirements and number of steps for needleless access device scrubbing prior to catheter flushes during medication administration process.
Study NCT06604026 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BD PosiFlush™
Description: Clinicians will be advised to follow and document the respective unit protocol, while using the standard pre-filled syringe (BD PosiFlush™ SP Syringe) and alcohol pad for scrubbing and flushing of NADs in the control arm of the study as the routine practice.~An independent nurse observer will observe and document any adverse events (e.g.~local skin reaction, or irritation, or allergic response, up to and including symptoms of anaphylaxis), compliance with needleless access device scrubbing before flushing, device success rate (encapsulation and removal) as well as the time requirements and number of steps for needleless access device scrubbing prior to catheter flushes during medication administration process.
Study NCT06660368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen
Description: Filgrastim/G-CSF 300 mcg/day for 6 days beginning 24 hours prior to multiagent chemotherapy (days 0-5), cladribine 5 mg/m2 given intravenously over 2 hours for 5 consecutive days (days 1-5), cytarabine given IV over 4 hours for 5 consecutive days (days 1-5) beginning 2 hours after the completion of cladribine, and mitoxantrone 16 mg/m2 given intravenously over 30 minutes for 3 days (days 1-3) after completion of cytarabine.
Study NCT06660368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen
Description: Filgrastim/G-CSF 300 mcg/day for 6 days beginning 24 hours prior to multiagent chemotherapy (days 0-5), cladribine 5 mg/m2 given intravenously over 2 hours for 5 consecutive days (days 1-5), cytarabine given IV over 4 hours for 5 consecutive days (days 1-5) beginning 2 hours after the completion of cladribine, and mitoxantrone 16 mg/m2 given intravenously over 30 minutes for 3 days (days 1-3) after completion of cytarabine.
Study NCT06660368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally, once daily, with food.
Study NCT06602544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Apparel
Description: A robotic apparel system is a portable, lightweight textile-based wearable robot that is worn around the waist and thighs. The apparel provides assistive flexion moment about the hip joint during the swing phase of gait by spooling in a cable that connects the thigh wraps to the front of the waist belt. Inertial measurement units embedded in the thigh wraps are used to control the timing of the robotic apparel assistance. Robotic apparel assistance magnitude is delivered as a small percentage of the bodyweight of the wearer.
Study NCT05239585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epilog device
Description: Pilot the use of wireless EEG technology in neonates with mild neonatal encephalopathy and neonates with spells to see if this device can be used to determine the risk for neonatal seizure and need for escalation of care and full scalp EEG
Study NCT06679309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated care plan
Description: Complex care plan facilitated by the integrated care lead with 90 day follow-up, 24/7 phone support and connection with resources and services
Study NCT06547177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fruit juice
Description: During labor, one group will follow the routine while the water group will only take water and fruit juice group will take water and fruit juice.
Study NCT05331508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gender-based violence screening, first-line support (LIVES) and reproductive coercion empowerment counseling (ARCHES)
Description: Providers will (1) introduce routine client screening for GBV, including intimate partner violence, sexual violence, and reproductive coercion using a standardized screening form, in FP and ANC services,(2) for individuals disclosing GBV, provide first-line response-empathetic counseling, including listening, inquiring about experiences sensitively, and validating experiences, helping clients develop safety plans, and providing support; (3) regardless of disclosure of GBV, provide counseling and information, education and communication (IEC) materials on IPV, including reproductive coercion, and FP options, to both FP and ANC clients.
Study NCT04763330 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Enhanced Usual Care (EUC) consists of Collaborative Safety Planning, a VA usual care practice. It is a tool that Veterans can use when they are in an acute suicidal crisis. The condition is considered enhanced because Veterans in this condition receive 6 sessions total, Safety Planning which is delivered in 1-2 sessions and 4-5 sessions of check-ins with a brief assessment. Safety Planning involves a worksheet completed by the patient in collaboration with a health provider.
Study NCT04763330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy (PST) plus EUC
Description: Veterans randomized to this condition received EUC and PST. EUC is delivered in both conditions to ensure the safety of all Veterans enrolled in the study. In addition to EUC, Veterans in this condition receive PST, which teaches patients a structured planful problem solving approach to: 1) identify problems and set goals, 2) generate alternative solutions, 3) select a solution based on cost-benefit analysis, and 4) devise and implement a plan for the solution and assess its effectiveness in solving the problem. This contemporary PST protocol also teaches tool kits to address obstacles highly pertinent to the challenges faced by older Veterans with mental health disorders and active suicidal ideation: emotion dysregulation, hopelessness, and feeling overwhelmed by too much information (brain overload) or stress.
Study NCT06644118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OL-101 infusion
Description: OL-101 infusion will be administered to patients via IV infusion at the assigned dose.
Study NCT04987411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of methane concentrations in exhaled breath
Description: To measure methane concentrations, a near-infrared laser technique-based photoacoustic apparatus will be attached to the exhalation outlet of the ventilator upon arrival of severely injured patients. Exhaled methane levels will be monitored continuously during the first 72 in-hospital hours and will be recorded at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission).
Study NCT04987411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Videomicroscopy of the sublingual microcirculation
Description: Orthogonal polarization spectral imaging technique (Cytoscan A/R, Cytometrics) will be used to visualize the microcirculation of the sublingual mucosa of the patients. The OPS technique utilizes reflected, polarized light at the wavelength of the isobestic point of oxyhemoglobin and deoxyhemoglobin (548 nm). The diminution of sublingual microcirculation can refer to circulatory redistribution due to hemorrhage. Sublingual microcirculation of the patients will be visualized and evaluated at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
Study NCT04987411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood gas and laboratory analysis
Description: Arterial blood gas analysis and laboratory testing of venous blood are routine examinations in clinical practice. Base deficit and lactate are considered as global markers of blood loss and shock, and can be obtained rapidly with blood gas analysis. Hemoglobin and hematocrit values can correspond to the severity of blood loss, and are measured routinely both from arterial and venous blood. Sampling of arterial and venous blood for blood gas and laboratory analyses will be performed at pre-determined time points (directly upon arrival, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
Study NCT04987411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hemodynamic monitoring
Description: Hemodynamic monitoring is an essential part of emergency trauma care. Non-invasive monitoring of blood pressure, heart rate and respiratory rate of patients will be started immediately upon arrival. After patients are stabilized, invasive arterial blood pressure (IABP) monitoring can be started. IABP is considered as the gold standard of blood pressure measurement in critical care as it reflects the fluctuations of blood pressure in real time. Blood pressure and heart rate values will be recorded at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
Study NCT06373185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided sacral erector spinae plane block
Description: Patients were received ultrasound-guided sacral erector spinae plane block, 1ml/kg %0.25 bupivacaine (max 20 ml), for postoperative pain management
Study NCT06373185 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided caudal block
Description: Patients were received ultrasound-guided caudal block, 1ml/kg %0.25 bupivacaine (max 20 ml), for postoperative pain management
Study NCT05472350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Breztri Aerosphere
Description: Breztri Aerosphere is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema).
Study NCT05472350 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo is 0.9% normal saline
Study NCT05301881 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: resection of the oligometastatic lesion(s)
Study NCT05301881 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: radiation of the oligometastatic lesion(s)
Study NCT05301881 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Radiofrequent ablation
Description: radiofrequent ablation of the oligometastatic lesion(s)
Study NCT05388266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mask ventilation
Description: Mask ventilation is performed under paratracheal pressure or no pressure in a randomized, crossover manner.
Study NCT05388266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mask ventilation
Description: Mask ventilation is performed under paratracheal pressure or no pressure in a randomized, crossover manner.
Study NCT04884243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CBT-006
Description: ophthalmic solution
Study NCT04884243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-006
Description: ophthalmic solution
Study NCT06178640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg film-coated tablet
Description: Simvastatin 40 mg film-coated tablet
Study NCT06178640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 40 mg film-coated tablet
Description: Simvastatin 40 mg film-coated tablet
Study NCT06178640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zocor 40 mg film-coated tablet
Description: Zocor 40 mg film-coated tablet (Simvastatin 40 mg film-coated tablet: Reference Product)
Study NCT06178640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zocor 40 mg film-coated tablet
Description: Zocor 40 mg film-coated tablet (Simvastatin 40 mg film-coated tablet: Reference Product)
Study NCT05714371 — intervention group
Intervention type: DRUG
Intervention: Nivolumab
Description: Patients receiving nivolumab
Study NCT05714371 — intervention group
Intervention type: DRUG
Intervention: Ipilimumab + nivolumab
Description: Patients receiving ipilimumab + nivolumab
Study NCT04274374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten-Free Diet
Description: Dietary supplement without gluten
Study NCT04274374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten Diet
Description: Dietary supplement with gluten
Study NCT06626997 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Kombucha tea
Description: During Visit 1 (week 0), a fasting blood test must be performed at the IMDEA Alimentación facilities to obtain different markers: blood lipids, blood glucose, etc. Approximately 20 mL will be extracted (for comparison, keep in mind that a donation requires 450 mL). The blood sample will be extracted by qualified nursing staff from the UNILABS Laboratory. The blood tests based on the security and privacy requirements for handling samples will be carried out by the same laboratory.~You will also be asked to provide the stool sample that you must have collected at home prior to attending that visit with the material provided at the screening visit (V0) and at the intermediate visit (V2).
Study NCT06626997 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kombucha tea
Description: During Visit 1 (week 0), a fasting blood test must be performed at the IMDEA Alimentación facilities to obtain different markers: blood lipids, blood glucose, etc. Approximately 20 mL will be extracted (for comparison, keep in mind that a donation requires 450 mL). The blood sample will be extracted by qualified nursing staff from the UNILABS Laboratory. The blood tests based on the security and privacy requirements for handling samples will be carried out by the same laboratory.~You will also be asked to provide the stool sample that you must have collected at home prior to attending that visit with the material provided at the screening visit (V0) and at the intermediate visit (V2).
Study NCT05714371 — intervention group
Intervention type: DRUG
Intervention: Pembrolizumab
Description: Patients receiving pembrolizumab
Study NCT05714371 — intervention group
Intervention type: DRUG
Intervention: Dabrafenib + trametinib
Description: Dabrafenib + trametinib
Study NCT05255601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified Dose on Specified Days
Study NCT05255601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified Dose on Specified Days
Study NCT05336643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofluorescence
Description: Assessment of pelvic sidewall with Firefly and Sensei
Study NCT05870332 — intervention group
Intervention type: DEVICE
Intervention: GI Genius (GIG)
Description: GIG is an artificial intelligence unit that assists human colonoscopist in real-time to detect polyps during colonoscopy.~Four months collection period prior to activating GIG, then four months with GIG, and Four months afterwards without GIG
Study NCT05434364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facilitated Tucking
Description: giving facilitated tucking before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
Study NCT05434364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swaddling
Description: swaddling before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
Study NCT05434364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone Position
Description: giving prone position before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
Study NCT05329311 — intervention group
Intervention type: PROCEDURE
Intervention: ERATS protocol applied
Description: Inflammatory parameters (such as; C-reactive protein (CRP), white blood cell count, neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), lymphocyte/monocytes ratio (LMR) of the operated patients by applying the ERATS protocol will be investigated.
Study NCT05329311 — intervention group
Intervention type: PROCEDURE
Intervention: ERATS protocol not applied
Description: Inflammatory parameters (such as; C-reactive protein (CRP), white blood cell count, neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), lymphocyte/monocytes ratio (LMR) of the operated patients by applying without the ERATS protocol will be investigated.
Study NCT05204368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Imipenem/Cilastatin and XNW4107
Description: Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for injection
Study NCT05204368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem 1g for injection